摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-碘-3-甲基苯甲酸 | 108078-14-4

中文名称
2-碘-3-甲基苯甲酸
中文别名
——
英文名称
2-iodo-3-methylbenzoic acid
英文别名
3-methyl-2-iodobenzoic acid;2-Iod-3-methyl-benzoesaeure
2-碘-3-甲基苯甲酸化学式
CAS
108078-14-4
化学式
C8H7IO2
mdl
MFCD00079764
分子量
262.047
InChiKey
PZUXUOZSSYKAMX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    150-153 °C (lit.)
  • 沸点:
    323.5±30.0 °C(Predicted)
  • 密度:
    1.867±0.06 g/cm3(Predicted)
  • 稳定性/保质期:
    如果按照规格使用和储存,则不会分解,没有已知危险反应。应避免与强氧化物接触。

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    LIGHT SENSITIVE
  • 安全说明:
    S22,S24/25
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2916399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    请将贮藏器保持密封,并存放在阴凉、干燥处。同时,确保工作环境有良好的通风或排气设施。

SDS

SDS:ca05f0a6e231857ef8c61223cdc8cbd2
查看
Material Safety Data Sheet

Section 1. Identification of the substance
2-Iodo-3-methylbenzoic acid
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
2-Iodo-3-methylbenzoic acid
Ingredient name:
CAS number: 108078-14-4

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7IO2
Molecular weight: 262.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen Iodide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-碘-3-甲基苯甲酸sodium periodate溶剂黄146 作用下, 反应 4.0h, 生成 3-methyl-2-iodosylbenzoic acid
    参考文献:
    名称:
    高价碘试剂区域选择性和立体选择性金催化亚酰胺酰氧基炔基化合成酰胺烯醇 2-碘苯甲酸酯
    摘要:
    多取代烯烃可通过金催化的炔酰胺与乙炔基苯并氧杂环戊烷 (EBX) 的酰氧基炔基化获得,具有完美的原子经济性。EBX 试剂转移羧酸盐和炔基实体。总的来说,这个级联包括原位生成炔基金 (III) 物质、立体选择性 C(sp)-C(sp 2 ) 键的形成和炔酰胺的炔基位置的 C-O 偶联。该反应在温和的条件下进行并接受广泛的底物。以良好至优异的产率获得了许多具有不同官能团的四取代酰胺烯醇 2-碘苯甲酸酯。DFT 计算解释了观察到的区域选择性。该反应的合成潜力通过一些选定的后续转化进一步证明。
    DOI:
    10.1021/acs.orglett.2c02161
  • 作为产物:
    描述:
    间甲基苯甲酸 在 palladium on activated charcoal 硫酸氢气硝酸 作用下, 以 乙醇 为溶剂, -10.0~30.0 ℃ 、101.33 kPa 条件下, 反应 3.5h, 生成 2-碘-3-甲基苯甲酸
    参考文献:
    名称:
    1,16-二羟基四亚苯基的合成,拆分和应用作为分子识别和组装中的新组成部分。
    摘要:
    本文涉及通过采用新型的NBS溴化途径合成1,16-二羟基四亚苯基(DHTP)(2)。(+/-)-DHTP 2成功解析为其旋光对映体,并转化为(+/-)-1,16-双(二苯基膦基)四亚苯基(BPTP)(26),其铂络合物BPTP-PtCl(2)( 27)。作为氢键供体,使外消旋和旋光的DHTP 2与4,4'-联吡啶组装形成优质的单晶。这些晶体的X射线衍射研究表明,(+/-)-2和4,4'-联吡啶之间的氢键配合物的晶体堆积不同于由(S)-2和4,4'形成的混合物-联吡啶。发现在(+/-)-2和4,4'-联吡啶的组装物中形成了具有交替手性的无限之字形链,而(S)-2和4,4' -联吡啶未能显示出相同的组装模式。(+/-)-2与4,4'-联吡啶形成交替的锯齿形链的原因很可能是由于这种超分子组装体的固有稳定性所致。还研究了在铂(II)方向上2和旋光性BINAP之间的手性识别。(1)H和(31)P N
    DOI:
    10.1021/jo0302408
  • 作为试剂:
    描述:
    cis-11,12-bis(hydroxymethyl)-9,10-dihydro-9,10-ethano-anthracene 在 Oxone2-碘-3-甲基苯甲酸 作用下, 以 乙腈 为溶剂, 反应 36.0h, 生成 4,9-benzo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-ol 、 4,9-benzo-3a,4,9,9a-tetrahydronaphtho[2,3-c]furan-1(3H)-one
    参考文献:
    名称:
    Facile organocatalytic domino oxidation of diols to lactones by in situ-generated TetMe-IBX
    摘要:
    The domino oxidation of diols to lactones is an important transformation, and catalytic protocols that allow this conversion smoothly are scarce. Capitalizing on the established reactivity of tetramethyl-IBX (TetMe-IBX) and its in situ generation in the presence of a co-oxidant, such as oxone, we have shown that a variety of diols can be converted to the corresponding lactones in respectable yields by employing the precursor of TetMe-IBX, namely, tetramethyl-o-iodobenzoic acid (TetMe-IA), as a catalyst in 5 mol % in the presence of 2 equiv of oxone. (c) 2014 Published by Elsevier Ltd.
    DOI:
    10.1016/j.tet.2014.01.034
点击查看最新优质反应信息

文献信息

  • [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2012145581A1
    公开(公告)日:2012-10-26
    Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    描述了二取代的八氢吡咯[3,4-c]吡咯化合物,这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用,比如失眠。
  • [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
    申请人:ROTTAPHARM SPA
    公开号:WO2013092893A1
    公开(公告)日:2013-06-27
    The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group -O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro- benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: C1 C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicylic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.
    该发明涉及以下式(I)的新化合物或其立体异构体、消旋体或混合物或其药学上可接受的盐:其中:R为苯基或含有1至3个来自S、N和O的杂原子的5-或6-成员杂芳环,这些环可以选择性地用n个基团Q取代;Q选自以下组成的一组:C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN、SO2CH3或一个基团-O[(CR1R2]pQ1;或Q可以是一个基团Q2;Q1为苯基,可以选择性地用n个取代基从以下组成的一组中取代:C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN或一个基团Q2;或对应于2,2-二氟苯并[d][1,3]二噁唑-4-基;Q2为含有至少一个氮原子的5-或6-成员杂芳基,可以选择性地用n个取代基从以下组成的一组中取代:C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN;P为6-成员杂芳基或8-11-成员双环杂芳基,可以选择性地用n个取代基从以下组成的一组中取代:C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN;R1为氢或C1-C3烷基;R2为氢或C1-C3烷基;n为1、2或3;p为0、1或2;并且在R对应于苯基时,P至少被一个CF3取代;制备这些化合物的方法,含有一个或多个式(I)化合物的药物组合物以及它们作为Orexin 1和Orexin 2受体的双重拮抗剂的用途。
  • Enantioselective Copper-Catalyzed Oxy-Alkynylation of Diazo Compounds
    作者:Durga Prasad Hari、Jerome Waser
    DOI:10.1021/jacs.7b04756
    日期:2017.6.28
    Enantioselective catalytic methods allowing the addition of both a nucleophile and an electrophile onto diazo compounds give a fast access into important building blocks. Herein, we report the highly enantioselective oxyalkynylation of diazo compounds using ethynylbenziodoxol-(on)e reagents and a simple copper bisoxazoline catalyst. The obtained α-benzoyloxy propargylic esters are useful building blocks
    允许将亲核试剂和亲电试剂添加到重氮化合物上的对映选择性催化方法可以快速进入重要的构建模块。在此,我们报告了使用乙炔基苯并氧醇-(on)e 试剂和简单的铜双恶唑啉催化剂对重氮化合物进行高度对映选择性的氧炔基化反应。获得的α-苯甲酰氧基炔丙酯是有用的结构单元,使用其他方法难以以对映体纯形式合成。所得产物可以有效地转化为邻二醇和α-羟基炔丙酯而不会损失对映体纯度。
  • A Convenient Synthesis of 1-Aryl- and 2-Aryl-Substituted Indazolones via Intramolecular C–N Coupling Promoted by KOt-Bu
    作者:Xue-jing Zhang、Ming Yan、Wei-juan Wang、Jia-hua Chen、Zi-cong Chen、Yu-feng Zeng、Albert Chan
    DOI:10.1055/s-0035-1562430
    日期:——
    Abstract A new method for the synthesis of 1-arylindazolones and 2-arylindazolones from N′-aryl-2-halobenzohydrazides promoted by KOt-Bu was developed. The difference of 2-halogen substituent exerted a significant effect on the distribution of the products. Two distinct reaction pathways are proposed for the generation of 1-arylindazolones and 2-arylindazolones, respectively. A new method for the synthesis
    摘要 提出了由KO t -Bu促进的N'-芳基-2-卤代苯并肼合成N-芳基-2-卤代苯并肼合成1-芳基吲哚酮和2-芳基吲哚酮的新方法。2-卤素取代基的差异对产物的分布具有显着影响。提出了两种不同的反应途径分别用于生成1-芳基吲哚酮和2-芳基吲哚酮。 提出了由KO t -Bu促进的N'-芳基-2-卤代苯并肼合成N-芳基-2-卤代苯并肼合成1-芳基吲哚酮和2-芳基吲哚酮的新方法。2-卤素取代基的差异对产物的分布具有显着影响。提出了两种不同的反应途径分别用于生成1-芳基吲哚酮和2-芳基吲哚酮。
  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    申请人:Chin Elbert
    公开号:US20100297073A1
    公开(公告)日:2010-11-25
    Compounds having the formula I wherein wherein R 1 , R 2 , R 3b , R 4a , R 4b , R 4c and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    具有公式I的化合物,其中R1、R2、R3b、R4a、R4b、R4c如本文所述定义,是丙型肝炎病毒NS5b聚合酶抑制剂。同时公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐